Privo’s cutting-edge PRV platform technology is a culmination of 12 years of research and development at MIT’s prestigious Bob Langer Lab and Privo’s own R&D facility. Our platform stands at the forefront of innovation, offering revolutionary solutions aimed to redefine drug delivery and therapeutic effectiveness.

Innovative Platform Attributes:

1. Nanoparticles (NPs)

Privo’s Nanoparticles are at the core of our technology, providing a sophisticated solution for encapsulating Active Pharmaceutical Ingredients (APIs). These nanoparticles serve a dual purpose by not only safeguarding volatile drugs but also facilitating controlled sustained release, leading to enhanced cell uptake. Our NP technology ensures the precise delivery of therapeutic agents, maximizing their efficacy while minimizing adverse effects.

2. Matrix

Our Matrix technology incorporates Generally Recognized as Safe (GRAS) excipients, playing a pivotal role in defining the dosage form for Privo’s drug products. Whether it’s injectables, patches, or hydrogels, Privo’s Matrix ensures the optimal delivery system for a diverse range of drugs. The versatility of the matrix empowers pharmaceutical professionals to tailor formulations that meet specific patient needs and optimize treatment outcomes.

2. Permeation Enhancer

Privo’s proprietary Permeation Enhancer is a game-changer in achieving uniform drug distribution and penetration throughout tissue. This technology ensures that therapeutic agents reach their target sites effectively, overcoming barriers that may hinder optimal drug delivery.